



Complications during hospitalization and at 30 days in the intensive cardiac care unit for patients with ST-elevation versus non-ST-elevation acute coronary syndrome

A protocol for systematic review and meta analysis

Qian Yang, MBBS, Jinlong Du, MBBS, Bing Wang, MD*

Abstract

Background: In this meta-analysis, we aimed to systematically compare the complications during hospitalization and at 30 days respectively, in intensive cardiac care unit (ICCU) for patients with ST elevation (STE) vs non-STE acute coronary syndrome (NSTE ACS).

Methods: Electronic search databases including http://www.ClinicalTrials.gov, EMBASE, Cochrane Central, Google Scholar, Web of Science, and MEDLINE were searched for publications comparing complications observed in STE ACS vs NSTE ACS patients admitted in ICCU, intensive care unit (ICU) or coronary care unit (CCU). This is a meta-analysis and risk ratios (RR) with 95% confidence intervals (CI) were used to illustrate the data following analysis by the RevMan 5.3 software.

Results: Six studies consisting of a total number of 25,604 participants (12,880 participants admitted due to STE ACS and 12,724 participants admitted due to NSTE ACS) were included. Our results showed that the total outcomes including severely abnormal electrocardiography (ECG) (RR: 1.48, 95% CI: 1.27–1.73; P=.00001) and mortality (RR: 1.83, 95% CI: 1.64–2.04; P=.00001) were significantly higher in patients with STE ACS. Re-infarction (RR: 0.86, 95% CI: 0.62–1.19; P=.37) and heart failure (RR: 1.04, 95% CI: 0.88–1.23; P=.62) were similarly manifested in those patients with ACS. However, the risk for recurrent angina was significantly higher with NSTE ACS (RR: 0.65, 95% CI: 0.46–0.92; P=.01).

Conclusions: Patients with STE ACS were at a higher risk for in-hospital and 30 days mortality in this analysis. In hospital, severely abnormal ECG was also significantly higher in this category of patients compared to NSTE ACS. However, re-admission for heart failure and re-infarction was similar in both groups. Future studies should be able to confirm this hypothesis.

Abbreviations: ACS = acute coronary syndrome, ECG = electrocardiography, ICCU = intensive cardiac care unit.

Keywords: complications, coronary care unit, intensive cardiac care unit, mortality, non-ST elevation acute coronary syndrome, reinfarction, ST elevation acute coronary syndrome

Editor: Abdelouahab Bellou.

QY and JD are the first co-authors and contributed equally to this work.

There was no external source of funding for this research.

The authors have no conflicts of interest to disclose.

The datasets generated during and/or analyzed during the present study are publicly available.

Department of Critical Care Medicine, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, Hubei, P.R. China.

^{*} Correspondence: Bing Wang, Department of Critical Care Medicine, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, Hubei, 434000, P.R. China (e-mail: iceking1204@163.com).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Yang Q, Du J, Wang B. Complications during hospitalization and at 30 days in the intensive cardiac care unit for patients with ST-elevation versus non-ST-elevation acute coronary syndrome: a protocol for systematic review and meta analysis. Medicine 2020;99:24(e20655).

Received: 6 November 2019 / Received in final form: 2 May 2020 / Accepted: 8 May 2020

http://dx.doi.org/10.1097/MD.000000000020655

1. Introduction

Since its existence, the intensive care unit (ICU) has been the main section of the hospital to handle severely ill patients with several co-morbidities and who would require urgent assistance and monitoring. From the time, they were set up, the intensive cardiac care units (ICCU) and the coronary care units (CCU) have been the main sections of specialized centers to handle and admit complicated and severely unstable patients with acute coronary syndrome (ACS).^[1,2]

Data on patients admitted to the ICCU or CCU have not been easy to obtain. The BLITZ-4 Qualita comprising of CCUs across Italy which was launched by the Italian Association of Hospital Cardiologists (Associazione Nazionale Medici Cardiologi Ospedalieri) aimed at collecting data of the patients with ST elevation (STE) and non-ST elevation (NSTE) ACS.^[3] In addition, the Italian Association of Hospital Cardiologists (ANMCO) and the Italian Health Institute (IHI) were involved to form the Italian network on ACS outcome (IN-ACS Outcome) study to further collect data based on outcomes of such patients admitted to the CCU.^[4] The French prospective study, Unite de Soins Intensifs Coronaires (USIC) was also set

Table 1

Outcomes (in hospital and at 30 days).

Study	In hospital outcomes	Outcomes at 30 days
Casella 2012 ^[8]	Re-infarction, angina or recurrent ischemia, supraventricular arrhythmia, major ventricular arrhythmia, high grade AV block, fatal or non-fatal stroke, heart failure or worsening, shock or killip IV, cardiac arrest, sepsis, other complications, acute renal dysfunction, modified TIMI major bleeding, length of stay in ICCU, in-ICCU mortality	_
Chiara 2003 ^[9]	Length of stay in CCU, Death, complicated hospital course, still admitted at 30 days	Death, re-infarction, re-admission for unstable angina, re- admission for heart failure, coronary angiography, coronary angioplasty, coronary artery bypass surgery
Gautam 2013 ^[10]	Cardiogenic shock	-
Hanania 2004 ^[5]	Killip IV, ventricular fibrillation, atrial fibrillation, 2nd or 3rd degree AV block, septal or cardiac rupture, stroke, mitral regurgitation	-
Olivari 2012 ^[3]	Length of stay in CCU, in-hospital mortality, hemorrhagic complications, re- infarction, stroke, hemorrhagic complications, blood transfusion, congestive heart failure, recurrence of angina	Death, re-infarction, stroke, hemorrhagic complications, blood transfusions, congestive heart failure, recurrence of angina
Rizzello 2012 ^[4]	Mortality, acute heart failure, re-infarction	Mortality, myocardial infarction, heart failure

AV=atrio-ventricular, ICCU=intensive coronary care unit, TIMI=thrombolysis in myocardial infarction.

up to follow-up on such ACS patients after discharge from CCU.^[5] However, the complications in STE and NSTE ACS patients who were admitted in the ICCU or CCU were never systematically compared.

In this meta-analysis, we aimed to systematically compare the complications during hospitalization and at 30 days respectively, in ICCU for patients with STE vs NSTE ACS.

2. Materials and methods

2.1. Searched databases and searched strategies

Electronic search databases: http://www.ClinicalTrials.gov, EMBASE, Cochrane Central, Google Scholar, Web of Science, and MEDLINE were searched for publications comparing complications observed in STE ACS vs NSTE ACS patients admitted in the ICCU, ICU, or CCU.

The following searched terms/phrases/texts were used to find publications:

- 1. ICU and ACS;
- 2. ICU and ACS;
- 3. ICU and ACS;
- 4. ICU and ACS;
- 5. ICU and myocardial infarction;
- 6. ICU and STE myocardial infarction;
- 7. ICU and STE ACS;
- 8. ICU and percutaneous coronary intervention;
- 9. ICU and coronary angioplasty.

The term "intensive care unit" was also replaced by "intensive cardiac care unit," "coronary care unit," and "cardiac care unit."

This search was restricted only to articles which were published in English language.

2.2. Major criteria for inclusion

Major criteria for inclusion were:

- 1. Studies comparing the complications of STE vs NSTE ACS patients admitted to the ICCU;
- 2. Studies that had an in-hospital follow-up or a follow-up time period of 30 days.

2.3. Major criteria for exclusion

The major criteria for exclusion were:

- Literature reviews, meta-analyses, case reports and correspondence;
- 2. Studies that were published in a different language apart from English;
- Studies that did not compare the complications of STE vs NSTE ACS patients admitted to the ICCU;
- 4. Duplication of studies.

2.4. Outcomes which were reported

Table 1 lists the outcomes which were reported during hospitalization and at 30 days following ICCU admission. The endpoints which were assessed included:

The endpoints which were assessed in

- 1. Re-infarction;
- 2. Recurrent angina;
- 3. Heart failure;
- 4. Stroke;
- Severely abnormal electrocardiography (ECG) including atrial and ventricular fibrillations, supraventricular tachycardia and atrio-ventricular blocks;
- 6. Mortality.

2.5. Data extraction and quality assessment

All the authors were independently involved in the data extraction process. First of all the complications which were reported in the hospital and at 30 days in each study were carefully extracted followed by the total number of participants in each group, the participants' enrollment time period, the type of study, the comorbidities of the participants, the age, and gender, the total number of events occurring in each subgroup were carefully extracted.

Disagreement concerning data extraction was discussed among the authors and finally solved by consensus.

The Newcastle Ottawa Scale (NOS),^[6] a tool to assess the methodological quality of the studies was used during the assessment of the studies, and grades were allotted: Grade A (low risk bias), Grade B (moderate risk of bias), and Grade C (high risk of bias).




Figure 1. Flow diagram for the study selection.

2.6. Statistical analysis

This is a meta-analysis and risk ratios (RR) with 95% confidence intervals (CI) were used to illustrate the data following analysis by the RevMan 5.3 software. The Q statistic test was used to assess heterogeneity. A significance level $P \le .05$ was set implying that any subgroup analysis with P value less or equal to .05 was considered statistically significant. Heterogeneity was also assessed with the I^2 statistic test and heterogeneity increased with an increasing I^2 value. In addition, if the heterogeneity was high, a random statistical model effect was used, whereas a fixed effect model was used if the heterogeneity was low.

Sensitivity analysis was also carried out by excluding each of the study one by one by turn, and any significant change in the result was observed.

Funnel plots were generated from the RevMan software and they were used to visually assess publication bias.

2.7. Ethical approval

This study does not include experiments that were carried out on humans or animals by any of the authors. Therefore, an ethical or a board review approval was not required.

3. Results

3.1. Search outcomes

One thousand three hundred fourteen (1314) publications were obtained. An initial evaluation was carried out to eliminate the less relevant studies. At first, 986 publications were eliminated.

Three hundred twenty-eight (328) full text articles were assessed for eligibility. A further 264 full text articles were eliminated for irrelevant contents.

Among the 64 remaining articles, 3 were eliminated since they were published in a different language, 5 were eliminated since they were literature reviews, 2 were letters of correspondence, 7 were case studies, 8 did not report the required outcomes, and 33 were duplicated studies. This selection process was based on the PRISMA guideline.^[7]

Finally, only 6 articles^[3-5,8-10] were selected for this analysis (Fig. 1).

3.2. Main features and baseline characteristics of the selected studies

The main features of the included studies have been listed in Table 2. All the studies were observational registries or cohorts. The patients were admitted to either the ICU, ICCU, or the CCU. The time period for enrollment of these participants ranged from the years 2000 to 2010. The six studies consisted of a total number of 25,604 participants (12,880 participants admitted due to STE ACS and 12,724 participants admitted due to NSTE ACS). Based on the NOS assessment, a grade B was allotted to the studies indicating a moderate risk of bias.

Table 3 lists the baseline features of the studies whereas Table 4 lists some of the major features of the participants. Majority of the participants admitted to ICCU were male patients with a mean age ranging from 64.5 to 71.0 years. Co-morbidities including diabetes mellitus, hypertension and atrial fibrillation were also given in Table 3. The types of coronary diseases, the

Main features of the studies.

	otaalool					
Study	Type of study	Type of ICU	Year of patients enrollment	No of patients with STE ACS (n)	No of patients with NSTE ACS (n)	Bias risk assessment grade
Casella 2012	OS	ICCU	2008	1492	2144	В
Chiara 2003	OS	CCU	-	1275	580	В
Gautam 2013	OS	ICU	2009-2010	24	18	В
Hanania 2004	OS	ICU	2000	1922	398	В
Olivari 2012	OS	ICCU	-	5854	5852	В
Rizzello 2012	OS	CCU	2005-2007	2313	3732	В
Total no of patients (n)				12,880	12,724	

CCU = coronary care unit, ICCU = intensive cardiac care unit, ICU = intensive care unit, NSTE ACS = non-ST elevation acute coronary syndrome, OS = observational study, STE ACS = ST elevation acute coronary syndrome.

Dasenne reatures	of the studies.	Males (%)	DM (%)	HBP (%)	ΔF (%
Table 3 Baseline features	of the studies				

	Age (years)	Males (%)	DM (%)	HBP (%)	AF (%)
Study	ST↑/NST↑	ST↑/NST↑	ST↑/NST↑	ST↑/NST↑	ST↑/NST↑
Casella 2012	-	65.5/66.0	22.5/28.5	_	7.00/10.0
Chiara 2003	66.0/68.0	71.0/69.0	20.0/24.0	51.0/63.0	-
Gautam 2013	64.5/64.5	57.9/57.9	43.8/43.8	36.9/36.9	-
Hanania 2004	65.0/68.0	73.0/73.0	21.0/23.0	45.0/55.0	-
Olivari 2012	68.0/71.0	72.7/66.6	20.3/30.6	53.3/67.2	-
Rizzello 2012	66.0/69.0	71.1/68.5	22.2/28.4	56.3/69.9	-

AF=atrial fibrillation, DM=diabetes mellitus, HBP=high blood pressure, NST↑=non-ST elevation acute coronary syndrome, ST↑=ST elevation acute coronary syndrome.

percentage of participants with renal dysfunction, prior myocardial infarction, prior revascularization, and the percentage of participants with Killip score 1 to 4 have been listed in Table 4.

3.3. Results of this analysis

Our analysis showed that the total outcomes including severely abnormal ECG (RR: 1.48, 95% CI: 1.27–1.73; P=.00001) and mortality (RR: 1.83, 95% CI: 1.64–2.04; P=.00001) were significantly higher in patients with STE ACS as shown in Figure 2. Stroke was not significantly different (RR: 1.23, 95% CI: 0.94–1.63; P=.13). Re-infarction (RR: 0.86, 95% CI: 0.62–1.19; P=.37) and heart failure (RR: 1.04, 95% CI: 0.88–1.23; P=.62) were also similarly manifested in those patients with ACS as shown in Figure 3. However, the risk for recurrent angina was significantly higher with NSTE ACS (RR: 0.65, 95% CI: 0.46–0.92; P=.01) as shown in Figure 3.

The outcomes were also separately assessed based on the in hospital follow-up and follow-up at 30 days, respectively.

During the in-hospital follow-up time period, severely abnormal ECG (RR: 1.48, 95% CI: 1.27–1.73; P=.00001) was significantly higher in patients with STE ACS as shown in Figure 4. In-hospital mortality was also significantly higher with STE ACS (RR: 2.12, 95% CI: 1.66–2.72; P=.00001) as shown in Figure 5. However, re-infarction and heart failure were not significantly different with (RR: 0.93, 95% CI: 0.73–1.19; P=.58) and (RR: 1.22, 95% CI: 0.87–1.71; P=.25), respectively during this in-hospital follow-up time period. Recurrence of angina was also significantly increased in patients with NSTE ACS (RR: 0.60, 95% CI: 0.40–0.90; P=.01).

At 30 days, heart failure (RR: 0.96, 95% CI: 0.87–1.05; P=.35) and re-infarction (RR: 0.90, 95% CI: 0.72–1.14; P=.40) were still similarly manifested in those patients with STE and NSTE ACS as shown in Figure 6. However, mortality was

01	r 4 m

Types of coronary artery disease and some basic features.

	Types of	Renal dysfunction (%)		Prior myocardial infarction (%)		Killip class 1 (%)	Killip class 2 (%)	Killip class 3 (%)	Killip class 4 (%)
Studies	participants	STE/NSTE	STE/NSTE	STE/NSTE	STE/NSTE	STE/NSTE	STE/NSTE	STE/NSTE	STE/NSTE
Casella 2012 ^[8]	STEMI and NSTEMI	5.00/8.00	3.00/5.50	14.0/31.0	10.0/24.5	_	-	-	-
Chiara 2003 ^[9]	STEMI and NSTEMI		-	15.0/27.0	5.20/13.0	79.6/79.0	15.9/13.1	2.60/6.50	1.90/1.40
Hanania 2004 ^[5]	STEMI and NSTEMI	4.00/6.00	_	16.0/28.0	5.50/13.0	78.0/78.0	14.0/14.0	5.50/6.00	3.00/2.00
Olivari 2012 ^[3]	STEMI and NSTEMI	4.70/11.9	_	8.20/17.3	5.55/13.9	-	14.7/15.1	5.90/7.50	5.90/7.50
Rizzello 2012 ^[4]	STEMI and NSTEMI	4.90/10.4	-	14.2/26.5	-	-	10.2/10.6	7.00/5.60	7.00/5.60

NSTE=non-ST elevation myocardial infarction, NSTEMI=non-ST elevation myocardial infarction, STE=ST elevation myocardial infarction, STEMI=ST elevation myocardial infarction, UA=unstable angina.

	STE A	cs	NSTE	ACS		Risk Ratio	Risk Ratio	Risk of Bias
Study or Subgroup			Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% Cl	ABCDEFG
1.1.1 Severely Abnor	nal Elect	rocardio	ography					
Casella2012	194	1492	174	2144	18.0%	1.60 [1.32, 1.94]	-	
Hanania2004	329	1922	53	398	11.0%	1.29 [0.98, 1.68]		
Subtotal (95% CI)		3414		2542	29.0%	1.48 [1.27, 1.73]	◆	
Total events	523		227					
Heterogeneity: Chi ² = 1		•	,.	41%				
Test for overall effect: 2	Z = 4.90 (I	P < 0.00	001)					
4.4.0 Charles								
1.1.2 Stroke	•	4.400	10	~ ~ ~ ~	4.00/	1 00 10 10 0 551		
Casella2012	9	1492	12	2144	1.2%	1.08 [0.46, 2.55]		
Hanania2004	19	1922	3	398	0.6%	1.31 [0.39, 4.41]	Ľ	
Olivari2012	95	5854 9268	76	5852 8394	9.6% 11.4%	1.25 [0.93, 1.69] 1.23 [0.94, 1.63]		
Subtotal (95% CI)	400	9200		0394	11.470	1.25 [0.94, 1.05]		
Total events	123		91	20/				
Heterogeneity: Chi ² = 0		•	,.	J%				
Test for overall effect: 2	2 = 1.50 (1	P = 0.13)					
1.1.3 Mortality								
Casella2012	76	1492	42	2144	4.3%	2.60 [1.79, 3.77]		
Chiara2003	96	1275	30	580	5.2%	1.46 [0.98, 2.17]		
Olivari2012	552	5854	311	5852	39.1%	1.77 [1.55, 2.03]		
Rizzello2012	135	2313	114	3732	11.0%	1.91 [1.50, 2.44]		
Subtotal (95% CI)		10934		12308	59.6%	1.83 [1.64, 2.04]	♦	
Total events	859		497					
Heterogeneity: Chi ² = 5				40%				
Test for overall effect: 2	Z = 11.02	(P < 0.0	0001)					
Total (95% CI)		23616		23244	100.0%	1.66 [1.53, 1.81]	•	
Total events	1505		815					
Heterogeneity: Chi ² = 1	6.42, df =	= 8 (P =)	0.04); l ² =	51%				
Test for overall effect: 2		•					0.01 0.1 1 10 Favours [STE ACS] Favours [NSTE	100
Test for subgroup diffe	rences: C	hi² = 9.6	7, df = 2	(P = 0.0	08), l² = 79	9.3%	Favours [STE ACS] Favours [NSTE	, ACS]
Risk of bias legend								
(A) Random sequence	generatio	n (selec	tion bias)					
(B) Allocation conceal	nent (sele	ction bia	is)					
(C) Blinding of participa	ants and p	ersonne	l (perforn	nance bi	as)			
(D) Blinding of outcome	e assessm	nent (del	ection bia	as)				
(E) Incomplete outcom	e data (atl	trition bia	as)					
(F) Selective reporting	(reporting	bias)						
(G) Other bias								
Figure 2. Comparin	g the ov	erall co	mplicatio	on risks	s in patier	nts with STE and N	STE ACS admitted to the Intensiv	ve cardiac care unit (Part I).

significantly higher with STE ACS (RR: 1.68, 95% CI: 1.47–1.92; P = .00001) as shown in Figure 6.

A summarized version reflecting the results of this analysis has been given in Table 5.

3.4. Sensitivity analysis and publication bias

Consistency in results was observed throughout following sensitivity analysis. There was only low evidence of publication bias as shown in Figures 7–9 which visually demonstrated assessment of publication bias using studies which were involved for overall outcome, in-hospital outcomes and outcomes observed at 30 days, respectively.

4. Discussion

In this present analysis, severely abnormal ECG (atrial and ventricular fibrillations, ventricular tachycardia, and atrioventricular blocks) and mortality were significantly higher in ICCU patients with STE ACS as compared to NSTE ACS. This result mainly reflected the complications observed during the hospitalization time period. However, even at 30 days follow-up, the risk of mortality was still significantly higher in patients with STE ACS. In contrast, our analysis showed that recurrent angina was significantly higher in the NSTE ACS patients when compared to the STE ACS participants. However, re-infarction and heart failure were similar during the in-hospital and followup at 30 days in both groups.

An analysis involving 10, 983 participants with NSTE ACS from 5 Italian nationwide registries (2001–2010) consisting of patients admitted to the CCU, showed that complications were less and there was a reduction in the 30 day mortality among patients with NSTE ACS. This was also the case in our current meta-analysis showing a significantly higher risk of mortality to be associated with the STE ACS patients.^[11]

In this present analysis, the mean age of the participants varied from 64.5 to 71.0 years. Other studies have shown this age factor to significantly contribute to the prognosis of ACS. Old age is a major predictor of mortality in patients with ACS.^[12] The Euroheart ACS survey^[13] which involved academic and nonacademic hospitals with or without catheterization laboratories, as well as with or without cardiac surgery facilities, and enrolling patients from the year 2000 to 2001, from 25 different countries, it was found that the rate of STE ACS was less in elder patients, but, however, in-hospital mortality was more likely in the subgroup of patients with STE ACS as demonstrated in this present analysis.

	STE A	CS	NSTE	ACS		Risk Ratio	Risk Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% Cl	ABCDEFG
1.1.1 Re-Infarction								
Casella2012	14	1492	21	2144	5.8%	0.96 [0.49, 1.88]		
Chiara2003	12	1275	7	580	3.9%	0.78 [0.31, 1.97]		
Olivari2012	134	5854	123	5852	11.2%	1.09 [0.85, 1.39]	+	
Rizzello2012	117	2313	280	3732	11.6%	0.67 [0.55, 0.83]	-	
Subtotal (95% CI)		10934		12308	32.4%	0.86 [0.62, 1.19]	•	
Total events	277		431					
Heterogeneity: Tau ² =	0.06; Chi ²	= 8.81,	df = 3 (P	= 0.03);	l² = 66%			
Test for overall effect:	Z = 0.90 (I	P = 0.37	.)					
1.1.2 Recurrent Angi	na							
Casella2012	67	1492	129	2144	10.6%	0.75 [0.56, 1.00]		
Chiara2003	29	1275	15	580	6.4%	0.88 [0.48, 1.63]		
Olivari2012	308	5854	609	5852	12.4%	0.51 [0.44, 0.58]	•	
Subtotal (95% CI)		8621		8576	29.4%	0.65 [0.46, 0.92]	\bullet	
Total events	404		753					
Heterogeneity: Tau ² =	0.07; Chi ²	= 8.12,	df = 2 (P	= 0.02);	l² = 75%			
Test for overall effect:	Z = 2.46 (I	P = 0.01)					
1.1.3 Heart failure								
Casella2012	178	1492	209	2144	11.9%	1.22 [1.01, 1.48]	-	
Chiara2003	12	1275	4	580	2.9%	1.36 [0.44, 4.21]		
Olivari2012	1275	5854	1354	5852	12.9%	0.94 [0.88, 1.01]	-	
Rizzello2012	73	2313	117	3732	10.6%	1.01 [0.76, 1.34]	+	
Subtotal (95% CI)		10934		12308	38.2%	1.04 [0.88, 1.23]	◆	
Total events	1538		1684					
Heterogeneity: Tau ² =	0.01; Chi ²	= 7.02,	df = 3 (P	= 0.07);	l² = 57%			
Test for overall effect:	Z = 0.49 (I	P = 0.62	:)					
Total (95% Cl)		30489		33192	100.0%	0.86 [0.70, 1.07]	•	
Total events	2219		2868					
Heterogeneity: Tau ² =	0.09; Chi ²	= 94.58	, df = 10	(P < 0.0	0001); l² = 8	39%		<u> </u>
Test for overall effect:	Z = 1.32 (I	P = 0.19)				0.01 0.1 1 10 1 Favours [STE ACS] Favours [NSTE A	
Test for subgroup diffe	erences: C	hi² = 6.2	0, df = 2	(P = 0.0)	5), l² = 67.7	%	Favours [STE ACS] Favours [NSTE A	
Risk of bias legend								
(A) Random sequence	e generatio	n (selec	tion bias)				
(B) Allocation conceal	ment (sele	ction bia	as)					
(C) Blinding of particip	ants and p	ersonne	el (perforr	nance bi	ias)			
(D) Blinding of outcom	e assessm	nent (de	tection bia	as)	,			
(E) Incomplete outcom		,		,				
(F) Selective reporting			,					
(G) Other bias		,						
()	ring the	overall (omplies	tion riel	ke in natio	ate with STE and NS	STE ACS admitted to the Intensive ca	rdiac caro unit (Part II)

Figure 3. Comparing the overall complication risks in patients with STE and NSTE ACS admitted to the Intensive cardiac care unit (Part II).

In this analysis, a significantly higher rate of recurrent unstable angina was observed in the NSTEMI group among all those patients who were admitted in CCU. Possible explanations could be the presence of collateral vessels, there might be a flow limiting condition for example a stable plaque, a small coronary embolism or vasospasm which might not be severe enough to cause an elevation in cardiac biomarkers.^[14] Conditions such as hypertension, tachycardia and cardio-toxic drugs might also be reasons which could induce an angina.^[15]

In this present analysis, data were insufficient to show an analysis for cardiogenic shock in patients with STE ACS. In a CCU in the National Hospital of Sri Lanka,^[16] where 139 consecutive patients were admitted with STE ACS, mortality in 4 patients were due to cardiogenic shock, indicating that this complication is also quite common in STE ACS patients admitted to ICCU. However, future studies should assess more of such complications in patients with ACS admitted to the ICCU.

Even though percutaneous coronary intervention is best suited for less complicated coronary artery disease, recent studies have shown that in more complicated coronary diseases, especially with involvement of the left main coronary artery, both percutaneous coronary intervention and coronary artery bypass surgery have proven to be equally effective, with no significant difference in complications.^[17] It should also be noted that in patients with acute myocardial infarction, thrombectomy could result in immediately improved angiographic results and better clinical outcomes when compared to conventional percutaneous coronary intervention.^[18] At last, it should be understood that managing ACS in an ICU setting requires professional skills and intense knowledge since complications which arise might not be easy to manage.

5. Limitations

Limitations of this analysis were as followed: The total number of studies which were included in this meta-analysis was less, but we could not improve this limitation since there was no other studies that satisfied the inclusion and exclusion criteria of this analysis. Secondly, due to the limited number of studies and due to the fact that all the endpoints were not reported in all the studies, each subgroup analysis assessing respective outcomes could not include all the studies. Moreover, confounding variables might

	STE A		NSTE			Risk Ratio	Risk Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI	ABCDEFG
1.2.1 Re-infarction								
Casella2012	14	1492	21	2144	4.7%	0.96 [0.49, 1.88]		
Olivari2012	62	5854	57	5852	15.7%	1.09 [0.76, 1.56]		
Rizzello2012	37	2313	77	3732	16.2%	0.78 [0.53, 1.14]		
Subtotal (95% CI)		9659		11728	36.6%	0.93 [0.73, 1.19]	•	
Total events	113		155					
Heterogeneity: Chi ² = 7	,	· ·	<i>,</i> ,	0%				
Test for overall effect:	Z = 0.56 (I	P = 0.58	5)					
1.2.2 Severely Abnor	mal ECG							
Casella2012	194	1492	174	2144	39.3%	1.60 [1.32, 1.94]	=	
Hanania2004	329	1922	53	398	24.1%	1.29 [0.98, 1.68]	-	
Subtotal (95% CI)		3414		2542	63.4%	1.48 [1.27, 1.73]	•	
Total events	523		227					
Heterogeneity: Chi ² = 7	1.70, df =	1 (P = 0	.19); l² = 4	41%				
Test for overall effect:	Z = 4.90 (I	P < 0.00	001)					
Total (95% CI)		13073		14270	100.0%	1.28 [1.12, 1.46]	•	
Total events	636		382					
Heterogeneity: Chi ² = ²	13.06, df =	= 4 (P =	0.01); l² =	69%			0.01 0.1 1 10 1	
Test for overall effect: 2	Z = 3.69 (I	P = 0.00	02)				Favours [STE ACS] Favours [NSTE A	
Test for subgroup diffe	rences: C	hi² = 9.7	5, df = 1	(P = 0.0	02), l² = 89	9.7%		.00]
Risk of bias legend								
(A) Random sequence	generatio	on (selec	tion bias)					
(B) Allocation concealr	nent (sele	ction bia	as)					
(C) Blinding of participa	ants and p	ersonne	el (perforn	nance b	ias)			
(D) Blinding of outcome				as)				
(E) Incomplete outcom			as)					
(\mathbf{F}) Selective reporting	(reporting	bias)						
(G) Other bias								

Figure 4. Comparing the in-hospital complication risks in patients with STE and NSTE ACS admitted to the Intensive cardiac care unit (Part I).




Figure 5. Comparing the in-hospital complication risks in patients with STE and NSTE ACS admitted to the Intensive cardiac care unit (Part II).

Study or Subgroup Events Total Weight M-H, Fixed, 95% Cl M-H, Fixed, 95% Cl A B C D E F G 1.3.1 Heart Failure		STE A	.cs	NSTE	ACS		Risk Ratio	Risk Ratio	Risk of Bias
1.3.1 Heart Failure Chiara2003 12 1275 4 580 0.4% 1.36 [0.44, 4.21] Olivar2012 646 5852 54.3% 0.95 [0.55, 1.05] [0.57, 1.05] Rizzello2012 73 2313 117 3732 7.1% 1.01 [0.76, 1.34] Subtotal (95% Cl) 9442 10164 61.9% 0.96 [0.87, 1.05] Total events 731 804 Heterogeneity: Chi ² = 0.56, df = 2 (P = 0.76); I ² = 0% Test for overall effect: Z = 0.34 (P = 0.35) 1.3.2 Re-Infarction Chiara2003 12 1275 7 580 0.8% 0.76 [0.54, 1.07] Subtotal (95% Cl) 9442 10164 12.0% 0.90 [0.72, 1.14] 101 Chaira2003 111 1275 38 5802 4.2% 1.33 [0.93, 1.90] Image: Chier State St	Study or Subaroup					Weight			
Olivari2012 646 5854 683 582 543% 0.95 $[0.85, 1.05]$ Rizzello2012 73 2313 117 3732 7.1% 1.01 $[0.76, 1.34]$ Subtotal (95% CI) 9442 10164 61.9% 0.96 $[0.87, 1.05]$ Total events 731 804 Heterogeneity: Ch ² = 2 (P = 0.5); P = 0%. Test for overall effect: Z = 0.94 (P = 0.35) 1.3.2 Re-Infarction Chiara2003 12 1275 7 580 0.8% 0.78 $[0.31, 1.97]$ Olivari2012 72 5854 66 5852 5.3% 1.09 $[0.78, 1.52]$ Rizzello2012 46 2313 98 3732 6.0% 0.76 $[0.54, 1.07]$ Subtotal (95% CI) 9442 10164 12.0% 0.90 $[0.72, 1.14]$ Total events 130 171 Heterogeneity: Ch ² = 2.33, df = 2 (P = 0.31); P = 14% Test for overall effect: Z = 0.85 (P = 0.40) 1.3.3 Mortality Chiara2003 111 1275 38 580 4.2% 1.33 $[0.93, 1.90]$ Olivari2012 315 5854 189 5852 15.0% 1.67 $[1.40, 1.99]$ Rizzello2012 135 2313 114 3732 6.9% 9.91 $[1.50, 2.44]$ Subtotal (95% CI) 9442 10164 26.1% 1.68 $[1.47, 1.92]$ Total events 561 341 Heterogeneity: Ch ² = 2.76, df = 2 (P = 0.25); P = 27% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 96.0% Test for overall effect: Z = 7.65 (P < 0.00001); P = 96.0% Test for overall effect: Z = 7.65 (P									
Olivari2012 646 5854 683 582 543% 0.95 $[0.85, 1.05]$ Rizzello2012 73 2313 117 3732 7.1% 1.01 $[0.76, 1.34]$ Subtotal (95% CI) 9442 10164 61.9% 0.96 $[0.87, 1.05]$ Total events 731 804 Heterogeneity: Ch ² = 2 (P = 0.5); P = 0%. Test for overall effect: Z = 0.94 (P = 0.35) 1.3.2 Re-Infarction Chiara2003 12 1275 7 580 0.8% 0.78 $[0.31, 1.97]$ Olivari2012 72 5854 66 5852 5.3% 1.09 $[0.78, 1.52]$ Rizzello2012 46 2313 98 3732 6.0% 0.76 $[0.54, 1.07]$ Subtotal (95% CI) 9442 10164 12.0% 0.90 $[0.72, 1.14]$ Total events 130 171 Heterogeneity: Ch ² = 2.33, df = 2 (P = 0.31); P = 14% Test for overall effect: Z = 0.85 (P = 0.40) 1.3.3 Mortality Chiara2003 111 1275 38 580 4.2% 1.33 $[0.93, 1.90]$ Olivari2012 315 5854 189 5852 15.0% 1.67 $[1.40, 1.99]$ Rizzello2012 135 2313 114 3732 6.9% 9.91 $[1.50, 2.44]$ Subtotal (95% CI) 9442 10164 26.1% 1.68 $[1.47, 1.92]$ Total events 561 341 Heterogeneity: Ch ² = 2.76, df = 2 (P = 0.25); P = 27% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 86% Test for overall effect: Z = 7.65 (P < 0.00001); P = 96.0% Test for overall effect: Z = 7.65 (P < 0.00001); P = 96.0% Test for overall effect: Z = 7.65 (P		12	1275	4	580	0.4%	1.36 [0.44, 4.21]		
Fizzello2012 73 2313 117 3732 7.1% 1.01 $[0.76, 1.34]$ Subtotal (95% CI) 9442 10164 61.9% 0.96 $[0.87, 1.05]$ Total events 731 804 Heterogeneity: Ch ² = 0.55, df = 2 (P = 0.76); P = 0% Test for overall effect: Z = 0.94 (P = 0.35) 1.3.2 Re-infarction Chiara2003 12 1275 7 580 0.8% 0.78 $[0.31, 1.97]$ Olivar2012 72 5854 66 5852 5.3% 1.09 $[0.78, 1.52]$ Rizzello2012 46 2313 98 3732 6.0% 0.76 $[0.54, 1.07]$ Subtotal (95% CI) 9442 10164 12.0% 0.90 $[0.72, 1.14]$ Total events 130 171 Heterogeneity: Ch ² = 2.65, ff = 2 (P = 0.31); P = 14% Test for overall effect: Z = 0.85 (P = 0.40) 1.3.3 Mortality Chiara2003 111 1275 38 580 4.2% 1.33 $[0.93, 1.90]$ Olivar2012 315 5854 189 5852 15.0% 1.67 $[1.40, 1.99]$ Rizzello2012 135 2313 114 3732 6.9% 1.91 $[1.50, 2.44]$ Subtotal (95% CI) 9442 10164 26.1% 1.68 $[1.47, 1.92]$ Total events 561 341 Heterogeneity: Ch ² = 2.76, df = 2 (P = 0.25); P = 27\% Test for overall effect: Z = 7.85 (P < 0.0001) Total (95% CI) 28326 30492 100.0% 1.14 $[1.06, 1.22]$ Total events 1422 1316 Heterogeneity: Ch ² = 5.63, df = 8 (P < 0.00001), P = 86% Test for overall effect: Z = 7.85 (P < 0.00001) Total (95% CI) 28326 30492 100.0% 1.14 $[1.06, 1.22]$ Total events 1422 1316 Heterogeneity: Ch ² = 2.76, df = 2 (P < 0.00001), P = 96.0% Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of outcome assessment (detection bias) (C) Blinding of outcome assessment (detection bias) (D) Blinding of outcome data (attrition bias) (F) Selective reporting (reporting bias)								· · · · · · · · · · · · · · · · · · ·	
Subtotal (95% CI) 9442 10164 61.9% 0.96 [0.87, 1.05] Total events 731 804 Heterogeneity: Ch ² = 0.55, df = 2 (P = 0.76); P = 0% Test for overall effect: Z = 0.94 (P = 0.35) 1.32 Re-infarction Chiara2003 12 1275 7 580 0.8% 0.78 [0.31, 1.97] Olivar2012 72 5854 66 5852 5.3% 1.09 [0.78, 1.52] Rizzello2012 46 2313 98 3732 6.0% 0.76 [0.54, 1.07] Subtotal (95% CI) 9442 10164 12.0% 0.90 [0.72, 1.14] Total events 130 171 Heterogeneity: Ch ² = 2.33, df = 2 (P = 0.31); P = 14% Test for overall effect: Z = 0.85 (P = 0.40) 1.33 Mortality Chiara2003 111 1275 38 580 4.2% 1.33 [0.93, 1.90] Olivar2012 315 5854 189 5852 15.0% 1.67 [1.40, 1.90] Rizzello2012 315 5854 198 5852 15.0% 1.67 [1.40, 1.90] Rizzello2012 315 5854 198 5852 15.0% 1.67 [1.40, 1.90] Rizzello2012 315 5854 341 Heterogeneity: Ch ² = 2.76, df = 2 (P = 0.25); P = 27% Test for overall effect: Z = 7.65 (P < 0.00001) Total events 1422 1316 Heterogeneity: Ch ² = 55.63, df = 8 (P < 0.00001) Total events 1422 1316 Heterogeneity: Ch ² = 48 (P = 0.0005) Test for overall effect: Z = 7.65 (P < 0.00001) Rizzello2012 10 164 2 (P < 0.00001), P = 96.0% Rizzello2012 10 164 2 (P < 0.00001), P = 96.0% Risk of blas legend. (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of outcome assessment (detection bias) (B) Blinding of outcome assessment (detection bias) (C) Blinding of outcome data (attrition bias) (E) nonpelete outcome data (attrition bias) (B) Blinding of outcome data (attrition bias) (C) Selective reporting (reporting thesa)								+	
Heterogeneity: $Chi^2 = 0.55$, $df = 2 (P = 0.76)$; $P = 0\%$ Test for overall effect: $Z = 0.34$ ($P = 0.35$) 1.3.2 Re-Infarction Chiara2003 12 1275 7 580 0.8% 0.78 [0.31, 1.97] Olivar2012 72 5854 66 5852 5.3% 1.09 [0.78, 1.52] Rizzello2012 46 2313 98 3732 6.0% 0.76 [0.54, 1.07] Subtotal (95% C) 9442 10164 12.0% 0.90 [0.72, 1.14] Total events 130 171 Heterogeneity: $Chi^2 = 2.33$, $df = 2 (P = 0.31)$; $P = 14\%$ Test for overall effect: $Z = 0.85$ ($P = 0.40$) 1.3.3 Mortality Chiara2003 111 1275 38 580 4.2% 1.33 [0.93, 1.90] Olivar2012 315 5854 189 5852 15.0% 1.67 [1.40, 1.99] Rizzello2012 135 2313 114 3732 6.9% 1.91 [1.50, 2.44] Subtotal (95% C) 9442 10164 26.1% 1.68 [1.47, 1.92] Total events 561 341 Heterogeneity: $Chi^2 = 2.65$ ($P < 0.00001$); $P = 86\%$ Test for overall effect: $Z = 3.48$ ($P = 0.00001$); $P = 86\%$ Test for overall effect: $Z = 3.48$ ($P = 0.00001$); $P = 86\%$ Test for subgroup differences: $Chi^2 = 49.60$, $df = 2 (P < 0.00001$), $P = 96.0\%$ Elik of bias legend. (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of outcome assessment (detection bias) (C) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)	Subtotal (95% CI)		9442		10164	61.9%		•	
Test for overall effect: $Z = 0.94$ (P = 0.35) 1.3.2 Re-Infarction Chiara2003 12 1275 7 580 0.8% 0.78 [0.31, 1.97] Olivari2012 72 5854 66 5852 5.3% 1.09 [0.76, 1.52] Rizzello2012 46 2313 98 3732 6.0% 0.76 [0.54, 1.07] Subtotal (95% CI) 9 442 10164 12.0% 0.90 [0.72, 1.14] Total events 130 171 Heterogeneity: Chi ² = 2.33, df = 2 (P = 0.31); l ² = 14% Test for overall effect: Z = 0.85 (P = 0.40) 1.3.3 Mortality Chiara2003 111 1275 38 580 4.2% 1.33 [0.93, 1.90] Olivari2012 315 5854 189 5852 15.0% 1.67 [1.40, 1.99] Rizzello2012 315 5854 189 5852 15.0% 1.67 [1.40, 1.99] Rizzello2012 315 5851 114 3732 6.9% 1.91 [1.50, 2.44] Subtotal (95% CI) 9 4442 10164 26.1% 1.68 [1.47, 1.92] Total events 561 341 Heterogeneity: Chi ² = 2.76, df = 2 (P = 0.25); l ² = 27% Test for overall effect: Z = 7.65 (P < 0.00001); l ² = 86% Test for overall effect: Z = 3.48 (P = 0.0005) Test for subgroup differences: Chi ² = 49.60, df = 2 (P < 0.00001); l ² = 86% Test for subgroup differences: Chi ² = 49.60, df = 2 (P < 0.00001); l ² = 96.0% (B) Allocation concealment (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (E) Incomplete outcome data (attrition bias) (E) Selective reporting (reporting bias)	Total events	731		804					
1.3.2 Re-Infarction Chiara2003 12 1275 7 580 0.8% 0.78 [0.31, 1.97] Olivar2012 72 5854 66 5852 5.3% 1.09 [0.78, 1.52] Rizzello2012 46 2313 98 3732 6.0% 0.76 [0.54, 1.07] Subtotal (95% CI) 9442 10164 12.0% 0.90 [0.72, 1.14] [0.90] [0.90] [0.72, 1.14] Heterogeneity: Chi ² = 2.3, df = 2 (P = 0.31); P = 14% Test for overall effect: Z = 0.85 (P = 0.40) [1.40, 1.99] [0.170, 1.92] [1.52] [1.40, 1.92] [1.40] [1.41]	Heterogeneity: Chi ² =	0.55, df = 2	2 (P = 0	.76); l² =	0%				
Chiara2003 12 1275 7 580 0.8% 0.78 [0.31, 1.97] Olivar2012 72 5854 66 5852 5.3% 1.09 [0.78, 1.52] Witcatl(95% Cl) 9442 10164 12.0% 0.90 [0.72, 1.14] Total events 130 171 Heterogeneity: Ch ² = 2.33, df = 2 (P = 0.31); l ² = 14% Test for overall effect: $Z = 0.85$ (P = 0.40) 1.3.3 Mortality Chiara2003 111 1275 38 580 4.2% 1.33 [0.93, 1.90] Olivar2012 315 5854 189 5852 15.0% 1.67 [1.40, 1.99] Rizzello2012 135 2313 114 3732 6.0% 1.91 [1.50, 2.44] Subtotal (95% Cl) 9442 10164 26.1% 1.68 [1.47, 1.92] Total events 561 341 Heterogeneity: Ch ² = 2.76, df = 2 (P = 0.25); l ² = 27% Test for overall effect: $Z = 7.85$ (P = 0.00001); l ² = 86% Total events 1422 1316 Heterogeneity: Ch ² = 55.63, df = 8 (P < 0.00001); l ² = 86% Total events 1422 1316 Heterogeneity: Ch ² = 55.63, df = 8 (P < 0.00001); l ² = 86% Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of paticipants and personnel (performance bias) (D) Blinding of paticipants and personnel (performance bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)	Test for overall effect:	Z = 0.94 (ł	P = 0.35)					
Olivari2012 72 5854 66 5852 5.3% 1.09 [0.78, 1.52] Rizzello2012 46 2313 98 3732 6.0% 0.76 [0.54, 1.07] Subtotal (95% Cl) 9442 10164 12.0% 0.90 [0.72, 1.14] Total events 130 171 Heterogeneity: Ch ² = 2.33, df = 2 (P = 0.31); $P = 14\%$ Test for overall effect: Z = 0.85 (P = 0.40) 1.3.3 Mortality Chiara2003 111 1275 38 580 4.2% 1.33 [0.93, 1.90] Olivari2012 315 5854 189 5852 15.0% 1.67 [1.40, 1.99] Rizzello2012 135 2313 114 3732 6.9% 1.91 [1.50, 2.44] Subtotal (95% Cl) 9442 10164 26.1% 1.68 [1.47, 1.92] Total events 561 341 Heterogeneity: Ch ² = 2.76, df = 2 (P = 0.25); $P = 27\%$ Test for overall effect: Z = 7.65 (P < 0.00001) Total [95% Cl) 28326 30492 100.0% 1.14 [1.06, 1.22] Total events 1422 1316 Heterogeneity: Chi ² = 55.63, df = 8 (P < 0.00001); $P = 86\%$ Test for overall effect: Z = 3.48 (P = 0.0005) Test for subgroup differences: Chi ² = 49.60, df = 2 (P < 0.00001), $P = 96.0\%$ Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (D) Blinding of outcome data (attrition bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)	1.3.2 Re-Infarction								
Rizzello2012 46 2313 98 3732 6.0% 0.76 $[0.54, 1.07]$ Subtotal (95% CI) 9442 10164 12.0% 0.90 $[0.72, 1.14]$ Total events 130 171 Heterogeneity: Ch ² = 2.33, df = 2 (P = 0.31); l ² = 14% Test for overall effect: Z = 0.85 (P = 0.40) 1.3.3 Mortality Chiara2003 111 1275 38 580 4.2% 1.33 $[0.93, 1.90]$ Olivari2012 315 5854 189 5852 15.0% 1.67 $[1.40, 1.99]$ Rizzello2012 135 2313 114 3732 6.9% 1.91 $[1.50, 2.44]$ Subtotal (95% CI) 9442 10164 26.1% 1.68 $[1.47, 1.92]$ Total events 561 341 Heterogeneity: Ch ² = 2.76, df = 2 (P = 0.25); l ² = 27% Test for overall effect: Z = 7.65 (P < 0.00001); l ² = 86% Test for overall effect: Z = 7.65 (P < 0.00001); l ² = 86% Test for overall effect: Z = 7.48 (P = 0.005) Test for overall effect: Z = 3.48 (P = 0.0005) Test for overall effect: Z = 3.48 (P = 0.0005) Test for overall effect: Z = 3.48 (P = 0.0005) Test for overall effect: Z = 3.48 (P = 0.0005) Test for overall effect: Z = 3.48 (P = 0.0005) Test for overall effect: Z = 3.48 (P = 0.0005) Test for overall effect: Z = 3.48 (P = 0.0005) (B) Allocation concealment (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)	Chiara2003	12	1275	7	580	0.8%	0.78 [0.31, 1.97]		
Subtotal (95% Cl) 9442 10164 12.0% 0.90 [0.72, 1.14] Total events 130 171 Heterogeneity: Chi ² = 2.33, df = 2 (P = 0.31); l ² = 14% Test for overall effect: Z = 0.85 (P = 0.40) 1.3.3 Mortality Chiara2003 111 1275 38 580 4.2% 1.33 [0.93, 1.90] Olivari2012 315 5854 189 5852 15.0% 1.67 [1.40, 1.99] • Rizzello2012 135 2313 114 3732 6.9% 1.91 [1.50, 2.44] • Subtotal (95% Cl) 9442 10164 26.1% 1.68 [1.47, 1.92] • Total events 561 341 - - - Heterogeneity: Chi ² = 2.76, df = 2 (P = 0.25); l ² = 27% - - - - Test for overall effect: Z = -7.65 (P < 0.00001); l ² = 86% - - - - Test for overall effect: Z = -3.48 (P = 0.00005) - - - - Test for overall effect: Z = -3.48 (P = 0.00005) - - - - - Test for subgroup differences: Chi ² = 49.60, df =		72					1.09 [0.78, 1.52]	-	
Total events 130 171 Heterogeneity: Chi ² = 2.33, df = 2 (P = 0.31); l ² = 14% Test for overall effect: Z = 0.85 (P = 0.40) 1.3.3 Mortality Chiara2003 111 1275 38 580 4.2% 1.33 [0.93, 1.90] Olivari2012 315 5854 189 5852 15.0% 1.67 [1.40, 1.99] Rizzello2012 135 2313 114 3732 6.9% 1.91 [1.50, 2.44] Subtotal (95% Cl) 9442 10164 26.1% 1.68 [1.47, 1.92] Total events 561 341 Heterogeneity: Chi ² = 2.76, df = 2 (P = 0.25); l ² = 27% Test for overall effect: Z = 7.65 (P < 0.00001) Total (95% Cl) 28326 30492 100.0% 1.14 [1.06, 1.22] Total events 1422 1316 Heterogeneity: Chi ² = 5.63, df = 8 (P < 0.00001); l ² = 86% Test for overall effect: Z = 3.48 (P = 0.0005) Test for subgroup differences: Chi ² = 49.60, df = 2 (P < 0.00001), l ² = 96.0% <u>Risk of bias legend</u> (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)		46		98					
Heterogeneity: $Chi^2 = 2.33, df = 2 (P = 0.31); P = 14\%$ Test for overall effect: $Z = 0.85 (P = 0.40)$ 1.3.3 Mortality Chiara2003 111 1275 38 580 4.2% 1.33 [0.93, 1.90] Olivari2012 315 5854 189 5852 15.0% 1.67 [1.40, 1.99] Rizzello2012 135 2313 114 3732 6.9% 1.91 [1.50, 2.44] Subtotal (95% Cl) 9442 10164 26.1% 1.68 [1.47, 1.92] Total events 561 341 Heterogeneity: $Chi^2 = 2.76, df = 2 (P = 0.25); P = 27\%$ Test for overall effect: $Z = 7.65 (P < 0.00001)$ Total (95% Cl) 28326 30492 100.0% 1.14 [1.06, 1.22] Total events 1422 1316 Heterogeneity: $Chi^2 = 55.63, df = 8 (P < 0.00001); P = 86\%$ Test for overall effect: $Z = 3.48 (P = 0.0005)$ Test for overall effect: $Z = 3.48 (P = 0.0005)$ Test for subgroup differences: $Chi^2 = 49.60, df = 2 (P < 0.00001), P = 96.0\%$ Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (E) Incomplete outcome data (attrittion bias) (F) Selective reporting (reporting bias)	, ,		9442		10164	12.0%	0.90 [0.72, 1.14]	•	
Test for overall effect: $Z = 0.85$ (P = 0.40) 1.3.3 Mortality Chiara2003 111 1275 38 580 4.2% 1.33 [0.93, 1.90] Olivari2012 315 5854 189 5852 15.0% 1.67 [1.40, 1.99] Rizzello2012 135 2313 114 3732 6.9% 1.91 [1.50, 2.44] Subtctal (95% CI) 9442 10164 26.1% 1.68 [1.47, 1.92] Image: the state st									
Chiara2003 111 1275 38 580 4.2% 1.33 [0.93, 1.90] Olivari2012 315 5854 189 5852 15.0% 1.67 [1.40, 1.99] Rizzello2012 135 2313 114 3732 6.9% 1.91 [1.50, 2.44] Subtotal (95% CI) 9442 10164 26.1% 1.68 [1.47, 1.92] Total events 561 341 Heterogeneity: Chi ² = 2.76, df = 2 (P = 0.25); l ² = 27% Test for overall effect: Z = 7.65 (P < 0.00001)	0 ,	,	· ·		14%				
Olivari2012 315 5854 189 5852 15.0% 1.67 [1.40, 1.99] Rizzello2012 135 2313 114 3732 6.9% 1.91 [1.50, 2.44] Subtotal (95% CI) 9442 10164 26.1% 1.68 [1.47, 1.92] Total events 561 341 Heterogeneity: Chi ² = 2.76, df = 2 (P = 0.25); l ² = 27% Test for overall effect: Z = 7.65 (P < 0.00001)	1.3.3 Mortality								
Rizzello201213523131143732 6.9% 1.91 [$1.50, 2.44$]Subtotal (95% CI)94421016426.1% 1.68 [$1.47, 1.92$]Total events561341Heterogeneity: Chi ² = 2.76, df = 2 (P = 0.25); l ² = 27%Test for overall effect: Z = 7.65 (P < 0.00001)	Chiara2003	111	1275	38	580	4.2%	1.33 [0.93, 1.90]		
Subtotal (95% Cl)94421016426.1%1.68 $[1.47, 1.92]$ Total events561341Heterogeneity: Chi² = 2.76, df = 2 (P = 0.25); l² = 27%Test for overall effect: Z = 7.65 (P < 0.00001)	Olivari2012	315	5854	189	5852	15.0%	1.67 [1.40, 1.99]	-	
Heterogeneity: $Chi^2 = 2.76$, $df = 2 (P = 0.25)$; $l^2 = 27\%$ Test for overall effect: $Z = 7.65 (P < 0.00001)$ Total (95% Cl)2832630492100.0%1.14 [1.06, 1.22]Total events14221316Heterogeneity: $Chi^2 = 55.63$, $df = 8 (P < 0.00001)$; $l^2 = 86\%$ 0.010.11Test for overall effect: $Z = 3.48 (P = 0.0005)$ 0.01 0.1110Test for subgroup differences: $Chi^2 = 49.60$, $df = 2 (P < 0.00001)$, $l^2 = 96.0\%$ Favours [STE ACS]Favours [NSTE ACS]Risk of bias legend(A) Random sequence generation (selection bias)(B) Allocation concealment (selection bias)Favours [STE ACS]Favours [NSTE ACS](C) Blinding of participants and personnel (performance bias)(B) Blinding of outcome assessment (detection bias)(E) Incomplete outcome data (attrition bias)(F) Selective reporting (reporting bias)(F) Selective reporting (reporting bias)		135		114				→	
Test for overall effect: $Z = 7.65$ (P < 0.00001)Total (95% Cl)2832630492100.0%1.14 [1.06, 1.22]Total events14221316Heterogeneity: Chi² = 55.63, df = 8 (P < 0.00001); l² = 86%	Total events	561		341					
Total (95% CI)2832630492100.0%1.14 [1.06, 1.22]Total events14221316Heterogeneity: Chi² = 55.63, df = 8 (P < 0.00001); l² = 86%	0 ,	,	· ·		27%				
Total events 1422 1316 Heterogeneity: Chi² = 55.63, df = 8 (P < 0.0001); I² = 86%		2 1.00 (1		001)	20.400	400.00/	4 4 4 54 00 4 001		
Heterogeneity: Chi ² = 55.63, df = 8 (P < 0.0001); l ² = 86% Test for overall effect: Z = 3.48 (P = 0.0005) Test for subgroup differences: Chi ² = 49.60, df = 2 (P < 0.00001), l ² = 96.0% <u>Risk of bias legend</u> (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)		1 100	20320	1010	30492	100.0%	1.14 [1.06, 1.22]	¥	
Test for overall effect: Z = 3.48 (P = 0.0005) 0.01 0.1 1 10 100 Test for subgroup differences: Chi² = 49.60, df = 2 (P < 0.00001), l² = 96.0%			0 (D -		12 0.00	v			
Test for subgroup differences: Chi ² = 49.60, df = 2 (P < 0.00001), l ² = 96.0% <u>Risk of bias legend</u> (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)	0 ,	,	•		1- = 80,	/o		0.01 0.1 1 10 1	00
Risk of bias legend		· ·		,) /D < 0	00001) 12	- 06 0%	Favours [STE ACS] Favours [NSTE A	CS]
 (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) 	0 1	erences. Ci	m ⁼ – 49.	60, ui – 2	2 (P < 0.	00001), 1-	- 90.0%		
 (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) 		aonoratio	n (solor	tion bios)	\ \				
 (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) 	· / ·	0		,)				
 (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) 	· · /	· ·		'	nance b	ias)			
 (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) 						100)			
(F) Selective reporting (reporting bias)	.,)				
	· · ·	· ·		,					
	.,		,						

Figure 6. Comparing the complication risks at 30 days in patients with STE and NSTE ACS admitted to the Intensive cardiac care unit.

Outcomes assessed	RR with 95% Cl	Р	ľ (%)
Overall analysis			
Re-infarction	0.86 [0.62-1.19]	.37	66
Recurrent angina	0.65 [0.46–0.92]	.01	75
Heart failure	1.04 [0.88–1.23]	.62	57
Severely abnormal ECG	1.48 [1.27–1.73]	.00001	41
Stroke	1.23 [0.94–1.63]	.13	0
Mortality (in hospital and at 30 days)	1.83 [1.64–2.04]	.00001	40
In hospital outcomes			
Re-infarction	0.93 [0.73–1.19]	.58	0
Recurrent angina	0.60 [0.40-0.90]	.01	82
Heart failure	1.22 [0.87–1.71]	.25	94

1.48 [1.27-1.73]

2.12 [1.66-2.72]

0.90 [0.72-1.14]

0.96 [0.87-1.05]

1.68 [1.47-1.92]

CI = confidence intervals, ECG = electrocardiography, RR = risk ratios.

Heart failure

Mortality

Severely abnormal ECG

In-hospital mortality

Outcomes at 30 days Re-infarction

41

61

14

0

27


.00001

.00001


.40


.35

.00001



have contributed to bias in this analysis. Also, during analysis of heart failure, we also included one study reporting re-hospitalization for heart failure during a follow-up time period of 1 year in the 30 day category. This might to a minor extent, affect the result for heart failure. In addition, there was one study which included a very minor number of participants; however, since the study satisfied the inclusion and exclusion criteria of this analysis, we could not have ignored it.





6. Conclusions

Patients with STE ACS were at a higher risk for in-hospital and 30 days mortality in this analysis. In hospital, severely abnormal ECG was also significantly higher in this category of patients compared to NSTE ACS. However, re-admission for heart failure and re-infarction was similar in both groups. Future studies should be able to confirm this hypothesis.

Author contributions

The authors Qian Yang, Jinlong Du, and Bing Wang were responsible for the conception and design, acquisition of data, analysis and interpretation of data, drafting the initial manuscript and revising it critically for important intellectual content. The first co-authors Qian Yang and Jinlong Du wrote this manuscript. All the authors agreed to and approved the manuscript as it is. Conceptualization: Qian Yang, Jinlong Du, Bing Wang. Data curation: Qian Yang, Jinlong Du, Bing Wang. Formal analysis: Qian Yang, Jinlong Du, Bing Wang. Funding acquisition: Qian Yang, Jinlong Du, Bing Wang. Investigation: Qian Yang, Jinlong Du, Bing Wang. Methodology: Qian Yang, Jinlong Du, Bing Wang. Project administration: Qian Yang, Jinlong Du, Bing Wang. Resources: Qian Yang, Jinlong Du, Bing Wang. Software: Qian Yang, Jinlong Du, Bing Wang. Supervision: Qian Yang, Jinlong Du, Bing Wang. Validation: Qian Yang, Jinlong Du, Bing Wang. Visualization: Qian Yang, Jinlong Du, Bing Wang. Writing - original draft: Qian Yang, Jinlong Du. Writing - review & editing: Qian Yang, Jinlong Du.

References

 Le May M, van Diepen S, Liszkowski M, et al. From coronary care units to cardiac intensive care units: recommendations for organizational, staffing, and educational transformation. Can J Cardiol 2016;32:1204–13.

- [2] Valentin A, Ferdinande P. ESICM Working Group on Quality ImprovementRecommendations on basic requirements for intensive care units: structural and organizational aspects. Intensive Care Med 2011;37:1575–87.
- [3] Olivari Z, Steffenino G, Savonitto S, et al. The management of acute myocardial infarction in the cardiological intensive care units in Italy: the 'BLITZ 4 Qualità' campaign for performance measurement and quality improvement. Eur Heart J Acute Cardiovasc Care 2012;1:143–52.
- [4] Rizzello V, Lucci D, Maggioni AP, et al. IN-ACS Outcome Investigators. Clinical epidemiology, management and outcome of acute coronary syndromes in the Italian network on acute coronary syndromes (IN-ACS Outcome study). Acute Card Care 2012;14:71–80.
- [5] Hanania G, Cambou JP, Guéret P, et al. Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry. Heart 2004;90:1404–10.
- [6] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
- [7] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339: b2700.
- [8] Casella G, Scorcu G, Cassin M, et al. Elderly patients with acute coronary syndromes admitted to Italian intensive cardiac care units: a Blitz-3 Registry sub-analysis. J Cardiovasc Med (Hagerstown) 2012;13:165–74.
- [9] Di Chiara A, Chiarella F, Savonitto S, et al. Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study. Eur Heart J 2003;24:1616–29.
- [10] Gautam MP, Sogunuru G, Subramanyam G, et al. Acute coronary syndrome in an intensive care unit of a tertiary care centre: the spectrum and coronary risk factors. JNMA J Nepal Med Assoc 2013;52:316–21.
- [11] De Luca L, Olivari Z, Bolognese L, et al. A decade of changes in clinical characteristics and management of elderly patients with non-ST elevation myocardial infarction admitted in Italian cardiac care units. Open Heart 2014;1:e000148.
- [12] Rubinstein R, Matetzky S, Beigel R, et al. Trends in management and outcome of acute coronary syndrome in women ≥80 years versus those <80 years in Israel from 2000-2016. Int J Cardiol 2019;281:22–7.</p>
- [13] Rosengren A, Wallentin L, Simoons M, et al. Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. Eur Heart J 2006;27:789–95.
- [14] Basit H, Malik A, Huecker MR. Non ST segment elevation (NSTEMI) myocardial infarction.

- [15] Kamińska J, Koper OM, Siedlecka-Czykier E, et al. The utility of inflammation and platelet biomarkers in patients with acute coronary syndromes. Saudi J Biol Sci 2018;25:1263–71.
- [16] Rahuman MB, Jayawardana JB, Francis GR, et al. Outcome of early coronary intervention for acute ST elevation myocardial infarction in a tertiary care cardiac centre in Sri Lanka. Ceylon Med J 2016;61: 26–31.
- [17] De Rosa S, Polimeni A, Sabatino J, et al. Long-term outcomes of coronary artery bypass grafting versus stent-PCI for unprotected left main disease: a meta-analysis. BMC Cardiovasc Disord 2017;17:240.
- [18] De Rosa S, Cirillo P, De Luca G, et al. Rheolytic thrombectomy during percutaneous coronary intervention improves long-term outcome in high-risk patients with acute myocardial infarction. J Interv Cardiol 2007;20:292–8.